Navigation Links
PreMD Successfully Completes Project for Health & Beauty Company
Date:6/20/2008

Provides Update on AMEX Appeal Hearing

TORONTO, June 20 /PRNewswire-FirstCall/ - Predictive medicine company PreMD Inc. (TSX: PMD; Amex: PME) today announced the successful completion of its agreement with one the world's leading health and beauty companies. As a result of the completion of this project, PreMD expects to enter into additional agreements with the company for further product development and other skin testing initiatives.

"We are very pleased to be working with a leading health and beauty company to jointly develop new and highly promising applications in skin-based tests," said Dr. Brent Norton, president and CEO of PreMD Inc.

Dr. Norton continued: "On June 4, PreMD announced it had appealed the recent decision made by American Stock Exchange (the "AMEX") to delist its stock. We have requested an oral hearing with the AMEX listing committee in order to present our strategy and progress in achieving our objectives. At this time we believe the hearing will not take place until late August or September. While there is no guarantee that we will be successful in maintaining our AMEX listing, we will continue to devote substantial efforts to achieving this and building value in the company."

About PreMD Inc.

PreMD Inc. is a leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection of life-threatening diseases. PreMD's cardiovascular products include a line of non-invasive skin cholesterol tests. PreMD's other skin cholesterol products include PREVU(x) LT, a skin cholesterol test designed for use in the life insurance industry. The Company's cancer tests include ColorectAlert(TM), LungAlert(TM) and a breast cancer test. PreMD's head office is located in Toronto, Ontario and its research and product development facility is at McMaster University in Hamilton, Ontario. For more information about PreMD, please visit http://www.premdinc.com.

This press release contains forward-looking statements. These statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the successful development or marketing of the Company's products, the competitiveness of the Company's products if successfully commercialized, the lack of operating profit and availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, product liability, reliance on third-party manufacturers, the ability of the Company to take advantage of business opportunities, uncertainties related to the regulatory process, and general changes in economic conditions. In addition, while the Company routinely obtains patents for its products and technology, the protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates.

Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. PreMD is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

(x) Trademark


'/>"/>
SOURCE PreMD Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. PreMD Reports Further Positive Meetings with the FDA
2. PreMD Appeals American Stock Exchange Delisting Notification
3. PreMD Reports First Quarter Results
4. PreMD Provides Update on FDA Review
5. PreMD Reports Fiscal 2007 Results
6. PreMD Inc. Completes Debenture Financing
7. PreMD Inc. Signs Agreement with Cosmetics Conglomerate
8. PreMD Inc. Announces Debenture Financing
9. PreMD Initiates FDA Review Process and Provides Corporate Update
10. PreMD Announces FDA Decision on POC Skin Cholesterol Test
11. PreMD Announces Valuable Data on PREVU(x) LT Life Insurance Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... , ... August 16, 2017 , ... ... Inc. has received a three-year grant totaling $975,000, renewing its funding from the ... and Human Services. , This funding marks, the fourth time the HRSA administration ...
(Date:8/16/2017)... ... August 16, 2017 , ... With a new PD diagnosis every nine ... , The grants are awarded through a competitive application process and reviewed by ... of backgrounds and expertise in all areas relevant to PD research. The SAB ...
(Date:8/16/2017)... VERO BEACH, Fla. (PRWEB) , ... August 16, ... ... living development and management company based in Vero Beach, announced today that two ... Florida Argentum, an organization that represents professionally managed senior living communities in Florida. ...
(Date:8/16/2017)... , ... August 16, 2017 , ... ... announces their latest new client win in the healthcare market, with Los Angeles-based ... to support healthcare staff and members. , AHF cares for nearly 800,000 individuals ...
(Date:8/16/2017)... ... August 16, 2017 , ... ... in AED (Automated External Defibrillator) machines to their local business community, Riverfront Fitness ... Arrow Benefits Group. AED machines are an integral part of treating those suffering ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... Tenn. , July 31, 2017 Three Tru-D SmartUVC ... Yongsan, South Korea . Tru-D, short for "Total Room ... and operating rooms after an environmental services (ES) professional cleans the area ... ... "Although the ...
(Date:7/28/2017)... 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), ... ended June 30, 2017, and updated its financial outlook ... For the fiscal third quarter, Hill-Rom reported earnings ... diluted share in the prior-year period. These results reflect ... diluted share primarily related to the non-cash write-down of ...
(Date:7/27/2017)... WARSAW, Ind., July 27, 2017  Zimmer Biomet Holdings, ... the quarter ended June 30, 2017.  The Company reported ... of 1.1% over the prior year period, and an ... approximately 240 basis points of contribution from the LDR ... from the second quarter of 2016, or 0.3% on ...
Breaking Medicine Technology: